Novel Developments in the Use of Antimetabolites
- 4 April 2014
- journal article
- review article
- Published by Taylor & Francis Ltd in Nucleosides, Nucleotides and Nucleic Acids
- Vol. 33 (4-6), 358-374
- https://doi.org/10.1080/15257770.2014.894197
Abstract
Antimetabolites are the most widely used and most efficacious group of anticancer drugs. Antimetabolites are also the oldest rationally designed anticancer drugs, targeted against RNA and DNA, and can, therefore, be considered as the first generation of targeted drugs. Unfortunately, resistance often develops, leading to the design of new antimetabolites, which either have a novel mechanism of action, bypass resistance or in combination enhance the effect of other drugs, such as another antimetabolite, other DNA, or protein kinase targeted anticancer drugs. Several novel antimetabolites are in clinical development. The cytidine-analog fluorocyclopentenylcytosine (RX-3117) is active in gemcitabine-resistant tumors and is activated by uridine-cytidine-kinase, can be incorporated into RNA and DNA and can downregulate DNA-methyltransferase-1. TAS-114 is a new generation dUTPase inhibitor. dUTPase normally prevents incorporation of dUTP and of the 5FU-nucleotide FdUTP into DNA. However, inhibition of dUTPase will enhance their incorporation, thereby increasing thymine-less cell-death. The formulation TAS-102 (trifluorothymidine and thymidine-phosphorylase-inhibitor) acts by incorporation into DNA and has shown efficacy in tumors progressing on 5FU therapy. Gemcitabine and cytarabine prodrugs were tested in model systems and have entered clinical evaluation. The elaidic-acid prodrugs of gemcitabine (CP-4126, CO101) and cytarabine (elacytarabine) failed in randomized Phase III studies. Two other gemcitabine prodrugs LY2334737 (gemcitabine with a valproic acid at the 5′-position) and NUC1031 (a 5′-arylphosphoamidate prodrug, with a side-chain at the 5′-phosphate) are in early clinical development. In summary, several novel antimetabolites show promise in clinical development, either because of a novel mechanism of action, or clever combination or by innovative prodrug design.Keywords
This publication has 48 references indexed in Scilit:
- New Challenges and Inspired Answers for Anticancer Drug Discovery and DevelopmentJapanese Journal of Clinical Oncology, 2013
- Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factorsBritish Journal of Cancer, 2011
- Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinomaCancer, 2010
- Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor modelsInvestigational New Drugs, 2010
- Mechanism of Inactivation of Human Ribonucleotide Reductase with p53R2 by Gemcitabine 5′-DiphosphateBiochemistry, 2009
- Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic StudyClinical Cancer Research, 2008
- Therapeutic potential of the dual‐targeted TAS‐102 formulation in the treatment of gastrointestinal malignanciesCancer Science, 2007
- Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cellsBritish Journal of Cancer, 2007
- The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas AdenocarcinomaClinical Cancer Research, 2004